Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Monte Rosa Therapeutics Analyst Ratings and Price Targets | NASDAQ:GLUE | Benzinga
Monte Rosa Therapeutics Inc has a consensus price target of $15.75 based on the ratings of 8 analysts. The high is $22 issued by UBS on October 13, 2022. The low is $10 issued by Wells Fargo on March 21, 2025. The 3 most-recent analyst ratings were released by Wells Fargo, Wedbush, and LifeSci Capital on March 21, 2025, March 21, 2025, and March 12, 2025, respectively. With an average price target of $15.33 between Wells Fargo, Wedbush, and LifeSci Capital, there's an implied 227.29% upside for Monte Rosa Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Wedbush
LifeSci Capital
Piper Sandler
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Monte Rosa Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/21/2025 | Buy Now | 113.45% | Wells Fargo | Derek Archila61% | $11 → $10 | Maintains | Equal-Weight | Get Alert |
| 03/21/2025 | Buy Now | 262.86% | Wedbush | Robert Driscoll44% | $15 → $17 | Maintains | Outperform | Get Alert |
| 03/12/2025 | Buy Now | 305.55% | LifeSci Capital | — | → $19 | Initiates | → Outperform | Get Alert |
| 12/19/2024 | Buy Now | 134.79% | Wells Fargo | Derek Archila61% | $14 → $11 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 09/12/2024 | Buy Now | 134.79% | Wedbush | Robert Driscoll44% | $11 → $11 | Reiterates | Outperform → Outperform | Get Alert |
| 08/12/2024 | Buy Now | 262.86% | Wells Fargo | Derek Archila61% | $18 → $17 | Maintains | Overweight | Get Alert |
| 06/28/2024 | Buy Now | 241.52% | Piper Sandler | Edward Tenthoff51% | $16 → $16 | Reiterates | Overweight → Overweight | Get Alert |
| 05/22/2024 | Buy Now | 134.79% | Wedbush | Robert Driscoll44% | $11 → $11 | Reiterates | Outperform → Outperform | Get Alert |
| 02/15/2024 | Buy Now | 134.79% | Wedbush | Robert Driscoll44% | → $11 | Initiates | → Outperform | Get Alert |
| 10/19/2023 | Buy Now | 134.79% | JP Morgan | Eric Joseph44% | $31 → $11 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 134.79% | Credit Suisse | Richard Law46% | → $11 | Reiterates | Neutral → Neutral | Get Alert |
| 05/12/2023 | Buy Now | 134.79% | Credit Suisse | Richard Law46% | → $11 | Reiterates | Neutral → Neutral | Get Alert |
| 03/17/2023 | Buy Now | 134.79% | Credit Suisse | Richard Law46% | $12 → $11 | Maintains | Neutral | Get Alert |
| 01/03/2023 | Buy Now | 305.55% | Wells Fargo | Derek Archila61% | → $19 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/13/2022 | Buy Now | 369.58% | UBS | Eliana Merle48% | → $22 | Initiates | → Buy | Get Alert |
| 08/15/2022 | Buy Now | 326.89% | Jefferies | Kelly Shi43% | → $20 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Monte Rosa Therapeutics (GLUE) stock?
The latest price target for Monte Rosa Therapeutics (NASDAQ:GLUE) was reported by Wells Fargo on March 21, 2025. The analyst firm set a price target for $10.00 expecting GLUE to rise to within 12 months (a possible 113.45% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Monte Rosa Therapeutics (GLUE)?
The latest analyst rating for Monte Rosa Therapeutics (NASDAQ:GLUE) was provided by Wells Fargo, and Monte Rosa Therapeutics maintained their equal-weight rating.
When was the last upgrade for Monte Rosa Therapeutics (GLUE)?
The last upgrade for Monte Rosa Therapeutics Inc happened on January 3, 2023 when Wells Fargo raised their price target to $19. Wells Fargo previously had an equal-weight for Monte Rosa Therapeutics Inc.
When was the last downgrade for Monte Rosa Therapeutics (GLUE)?
The last downgrade for Monte Rosa Therapeutics Inc happened on December 19, 2024 when Wells Fargo changed their price target from $14 to $11 for Monte Rosa Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Monte Rosa Therapeutics (GLUE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monte Rosa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monte Rosa Therapeutics was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.
Is the Analyst Rating Monte Rosa Therapeutics (GLUE) correct?
While ratings are subjective and will change, the latest Monte Rosa Therapeutics (GLUE) rating was a maintained with a price target of $11.00 to $10.00. The current price Monte Rosa Therapeutics (GLUE) is trading at is $4.68, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
